Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0V9ZL
|
||||
Former ID |
DIB001394
|
||||
Drug Name |
FCE-28161
|
||||
Synonyms |
PNU-166945; Lodeca[3,4]benz[1,2-b]oxet-5-one; Copolymer of N-(2-hydroxypropyl)methacrylamide,methacryloylglycine 2-hydroxypropylamide and [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(2R,3S),11beta,12alpha,12aalpha,12balpha]]-6,12b-diacetoxy-9-[3-benza; Mido-2-(methacryloyl-glycyl-L-phenylalanyl-L-leucyl-glycyloxy)-3-phenylpropionyloxy]-12-benzoyloxy-4,11-dihydroxy-4a,8,13,13-tetramethyl-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyc
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Discontinued in Phase 1 | [546352] | ||
CAS Number |
CAS 154330-65-1
|
||||
Target and Pathway | |||||
Target(s) | Tubulin | Target Info | Modulator | [550854], [551871] | |
References | |||||
Ref 550854 | CN patent application no. 101065129, A combination of n-(3-metoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer. | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.